|Bid||250.00 x 1100|
|Ask||301.00 x 1100|
|Day's range||251.84 - 271.51|
|52-week range||162.29 - 327.32|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||125.12|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||318.11|
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences. Stifel’s 2021 Virtual Healthcare Conference being held November 15-17. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, November 17, at 8:00 a.m. EST.Stephens Annual Investment Conference being held December 1-3.
Sets Baseline and Provides SASB, GRI Core and SDG DisclosuresWALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Company’s website. Repligen’s 2020 Sustainability Report provides an overview of the Company’s environmental, social and governance (ESG) performance in 2020 and into 2021, and provides disclosures aligned to three key reporting frameworks; the Value Reporting Foundation’s SASB Medic
Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.